US20080196711A1 - Method and apparatus for delivering an additive with a cpap machine - Google Patents
Method and apparatus for delivering an additive with a cpap machine Download PDFInfo
- Publication number
- US20080196711A1 US20080196711A1 US12/035,818 US3581808A US2008196711A1 US 20080196711 A1 US20080196711 A1 US 20080196711A1 US 3581808 A US3581808 A US 3581808A US 2008196711 A1 US2008196711 A1 US 2008196711A1
- Authority
- US
- United States
- Prior art keywords
- additive
- reservoir
- cpap
- machine
- air flow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000654 additive Substances 0.000 title claims abstract description 139
- 230000000996 additive effect Effects 0.000 title claims abstract description 123
- 238000000034 method Methods 0.000 title claims abstract description 12
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 22
- 125000003118 aryl group Chemical group 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000012530 fluid Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000002483 medication Methods 0.000 description 11
- 201000002859 sleep apnea Diseases 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 229940013181 advil Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- 229940060515 aleve Drugs 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229940072651 tylenol Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- IMWZZHHPURKASS-UHFFFAOYSA-N Metaxalone Chemical compound CC1=CC(C)=CC(OCC2OC(=O)NC2)=C1 IMWZZHHPURKASS-UHFFFAOYSA-N 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 240000004760 Pimpinella anisum Species 0.000 description 1
- 235000012550 Pimpinella anisum Nutrition 0.000 description 1
- 241000882890 Renova Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 244000297179 Syringa vulgaris Species 0.000 description 1
- 235000004338 Syringa vulgaris Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- GYMWQLRSSDFGEQ-ADRAWKNSSA-N [(3e,8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17r)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 GYMWQLRSSDFGEQ-ADRAWKNSSA-N 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229940008201 allegra Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 229940015273 buspar Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 235000020289 caffè mocha Nutrition 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229940047493 celexa Drugs 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229940088529 claritin Drugs 0.000 description 1
- 229940070380 claritin-d Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 229940063123 diflucan Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229940085392 excedrin Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229940032148 fioricet Drugs 0.000 description 1
- 229940099283 flexeril Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- MYWUZJCMWCOHBA-SECBINFHSA-N levmetamfetamine Chemical compound CN[C@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-SECBINFHSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940072709 motrin Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- KJNFMGMNZKFGIE-UHFFFAOYSA-N n-(4-hydroxyphenyl)acetamide;5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)NC1=CC=C(O)C=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O KJNFMGMNZKFGIE-UHFFFAOYSA-N 0.000 description 1
- 229940002297 nasacort Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229940059527 renova Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229940041735 rexall Drugs 0.000 description 1
- 229940116674 robitussin Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940105580 skelaxin Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 229940061368 sonata Drugs 0.000 description 1
- 229940089453 sudafed Drugs 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229940054492 unisom Drugs 0.000 description 1
- 229940108442 valtrex Drugs 0.000 description 1
- 229940087652 vioxx Drugs 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 229940009065 wellbutrin Drugs 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- 229940020965 zoloft Drugs 0.000 description 1
- 229940018503 zyban Drugs 0.000 description 1
- 229940036139 zyrtec Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
- A61M16/16—Devices to humidify the respiration air
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0057—Pumps therefor
- A61M16/0066—Blowers or centrifugal pumps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
Definitions
- the present invention relates to treatments for Sleep Apnea. More specifically, the present invention relates to an improved CPAP machine and methods of using a CPAP machine to provide an aromatic or therapeutic additive in the air flow provided to the patient.
- Sleep Apnea is an over-relaxation of the soft tissue in the back of the throat that causes a cessation of breathing during sleep states. The breathing cessation can cause a lack of oxygen that results in drowsiness and sleep disorders during waking hours.
- CPAP continuous positive airway pressure
- One treatment for Sleep Apnea is a continuous positive airway pressure (“CPAP”) machine, which provides a continuous flow of air through the nostrils via a mask. The flow of air works to maintain an open airway. Sleep Apnea sufferers must wear the mask for the entire night.
- One common component of a CPAP machine is a humidifier. Prior to applying the flow of air to the patient, the air is passed through the humidifier to add moisture to the air, thus helping to prevent the patient's nasal passages from drying out.
- One disadvantage of existing CPAP machines is that the moist air that is provided to the patient is often stale or even has an unpleasant smell or taste.
- a further disadvantage is that the existing machines provide nothing more than moist air to the patient.
- the present invention in one embodiment, is a method of delivering additive with a continuous positive airway pressure (“CPAP”) machine.
- the method includes mixing an additive with humidifier water and providing the additive to the patient with the CPAP machine.
- the additive can be an aromatic additive or a therapeutic additive.
- the present invention in another embodiment, is an apparatus for delivering an additive to a continuous positive airway pressure (“CPAP”) machine.
- the apparatus includes an additive delivery device associated with a reservoir of the CPAP machine.
- the apparatus also includes a flow control device associated with the delivery device and configured to control delivery of the additive to the CPAP machine.
- the present invention is a packaged formulation for delivering an additive in a continuous positive airway pressure (“CPAP”) machine.
- the formulation includes an additive and instructions for use of the additive with the CPAP machine.
- the additive is an aromatic additive or a therapeutic additive.
- FIG. 1 is a schematic diagram of a CPAP machine, according to one embodiment of the present invention.
- FIG. 2 is a schematic diagram of a CPAP machine, according to an alternative embodiment of the present invention.
- the present invention relates to an improved CPAP machine and a method of providing air flow to a patient having an aromatic or therapeutic additive.
- the aromatic additive provides a pleasant aroma to the air flow delivered to the patient, thus eliminating any unpleasant smell or taste associated with the air delivered by the CPAP machine.
- the therapeutic additive allows the patient to receive treatment not only for Sleep Apnea, but also for any other illness that can be treated by inhalation of an appropriate substance.
- FIG. 1 depicts a CPAP machine 50 according to one embodiment of the present invention.
- the machine 50 has a flow generator 52 , a reservoir 56 , and a mask 18 .
- the delivery component 14 has an inlet port 26 and a metering component 62 .
- a tube 54 connects the flow generator 52 to the reservoir 56
- a tube 60 connects the reservoir 56 to the mask 62 .
- the flow generator 52 is configured to create an air flow that is provided to the reservoir 56 and then the mask 62 via the tubes 54 , 60 .
- the flow generator 52 can be any known flow generator for a CPAP machine.
- the additive is added to the reservoir 56 through the inlet port 58 .
- a metering component 64 is configured to deliver the additive over time to the reservoir 56 at a metered or regulated rate. That is, the metering component 64 is configured to regulate or control over time the amount of additive that is delivered to the reservoir 56 .
- the metering component 64 is a metering dial similar to the device used to control intravenous injection flow rates. That is, the additive is placed into a flow line that passes through the dial and is regulated by turning the dial to pinch or open the line, thereby regulating the amount of additive that can pass through.
- the metering component 64 is a ball-valve system, in which a canal that allows flow of the additive can be blocked by a ball in the canal.
- the ball is configured to have at least one hole in it, and the ball can be turned by use of a handle connected to the ball.
- the ball is turned so that the hole creates a passage in the canal, flow of the additive through the canal occurs.
- the ball is turned so that the canal is completely blocked, flow of the additive is blocked.
- the amount of flow can be regulated by regulating the size of the passage by controlling how much the ball is turned in the canal.
- this device can be turned to provide various sized holes, thus allowing the additive to flow through to the reservoir 56 at a controlled rate.
- any known system for timed metering or regulation of the flow of a fluid can be used with the present invention.
- the additive is delivered directly to the reservoir 56 without any metering or flow regulation.
- the reservoir 56 in accordance with one embodiment, is configured to hold water and receive into the water the additive delivered through the inlet port 58 .
- the reservoir 56 is configured to allow the mixing of the additive into the water.
- Air flow passes through the reservoir 56 from the flow generator 52 to the mask 62 .
- the reservoir 56 is configured to allow the air flow to take up moisture in the form of the water and additive (be “humidified” with the water and additive) and further allow that air flow to pass out of the reservoir 56 and to the mask 62 .
- the reservoir 56 can be any known reservoir used with CPAP machines to humidify air flow.
- the mask 62 is configured to be placed on the patient's face and deliver the humidified air flow with the additive to the patient in such a fashion as to prevent Sleep Apnea.
- the mask 62 can be any known mask for use with CPAP machines to deliver the air flow to the patient.
- an aromatic additive is added to the inlet port 58 .
- the additive is in concentrate form.
- the additive is in pre-mixed form.
- the additive is in any form capable of being added to the CPAP machine.
- the aromatic additive in accordance with one aspect of the invention, is a fragrance.
- the additive can be chosen from, but is not limited to, any of the following aromatic additives, including lilac, evergreen, menthol, jasmine, eucalyptus, floral, lemon, lime, orange, tangerine, peppermint, strawberry, cherry, anise, honey, mint, vanilla, mocha.
- the aromatic additive is any known pleasant fragrance that can make the air flow more pleasant for the patient.
- the air flow is generated by the flow generator 52 and provided to the reservoir 56 .
- the aromatic additive is added to the reservoir 56 .
- the additive is delivered in a timed metering fashion or by any other method of flow regulation. Alternatively, the additive is delivered without flow regulation. The rate of delivery or the amount of the additive will vary depending on the additive and the size of the reservoir.
- the air is “humidified.” That is, a portion of the water and aromatic additive is taken up by the air and is delivered as a humidified air flow to the mask 62 .
- a therapeutic additive is added to the reservoir 56 .
- the additive is in concentrate form.
- the additive is in pre-mixed form.
- the additive is in any form capable of being added to the CPAP machine.
- the therapeutic additive in accordance with one aspect of the invention, is any substance with therapeutic effect that can be administered by inhalation.
- the additive can be chosen from, but is not limited to, any substance that treats any of the following ailments or illnesses, including sinus ailments, throat ailments, chest ailments, headaches, allergies, flu, cold, menstrual cramps, and insomnia.
- the additive can be chosen from, but is not limited to, any of the following therapeutic substances, including antihistamines, decongestants, anti-inflammatories, anti-depressants, vitamins, glucose, and chloraseptics.
- the therapeutic additive is any known substance having therapeutic effects that can be administered to the patient by inhalation.
- Non-limiting exemplary additives for pain relief, including some prescription medications include certain products sold under brand names such as Tylenol®, Motrin®, Advil®, Excedrin®, Aleve®, Celebrex®, Vioxx®, Flextra-DS®, Fioricet®, and Tramadol®.
- Non-limiting exemplary additives for menstrual relief include certain products sold under the brand name Pamprin®.
- Non-limiting exemplary additives for women's health, including some prescription medications include certain products sold under such brand names as Ortho Tri-Cyclen®, Nordette 28®, Triphasil®, Diflucan®, and Estradiol®.
- Non-limiting exemplary sleep aid additives including some prescription medications, include certain products sold under such brand names as Unisom®, Ambier®, and Sonata®.
- Non-limiting exemplary additives for arthritic relief include certain products sold under the brand name Tylenol®.
- Non-limiting exemplary vitamin additives include all known vitamins such as A, B-12, C, E, etc.
- Non-limiting exemplary vitamin additives include certain products sold under such brand names as Centrum®, Rexall®, Sundown®, Nature Made®, Natures Valley®, and Swanson Health®.
- Non-limiting exemplary additives for relief from viruses and/or infections, including some prescription medications include such products as penicillin and amoxicillin.
- Non-limiting exemplary muscle-relaxant additives include products sold under such brand names as Skelaxin®, Soma®, Flexeril®, and Zanflex®.
- Non-limiting exemplary additives for anxiety or depression, including some prescription medications include products under such brand names as Buspar®, Paxil®, Prozac®, Zoloft®, Wellbutrin®, and Celexa®.
- Non-limiting exemplary skin care additives, including some prescription medications include products such as retin A and products under such brand names as Renova®.
- Non-limiting exemplary additives for sexual or genital health, including some prescription medications include products under such brand names as Acyclovir® and Valtrex®.
- Non-limiting exemplary smoke-cessation additives, including some prescription medications include products under the brand name Zyban®.
- the air flow is generated by the flow generator 52 and provided to the reservoir 56 .
- the therapeutic additive is added to the reservoir 56 .
- the additive is delivered in a timed metering fashion or by any other method of flow regulation. Alternatively, the additive is delivered without flow regulation. The rate of delivery or the amount of the additive will vary depending on the prescribed application of the additive and the size of the reservoir.
- the air is “humidified.” That is, a portion of the water and therapeutic additive is taken up by the air and is delivered as a humidified air flow to the mask 62 .
- any aromatic or therapeutic additive disclosed herein can be added to the reservoir of any existing CPAP machine.
- the additive is provided in pre-mixed form.
- the additive is provided in concentrate form.
- the additive is in any form capable of being added to the reservoir of any existing CPAP machine.
- FIG. 2 depicts a CPAP machine 10 according to an alternative embodiment of the present invention.
- the machine 10 has a flow generator 12 , a delivery component 14 , a reservoir 16 , and a mask 18 .
- the delivery component 14 has an inlet port 26 and a metering component 28 .
- a tube 20 connects the flow generator 12 to the delivery component 14
- a tube 22 connects the delivery component 14 to the reservoir 16
- a tube 24 connects the reservoir 16 to the mask 18 .
- the flow generator 12 is configured to create an air flow that is provided through the delivery component 14 to the reservoir 16 and then the mask 18 via the tubes 20 , 22 , 24 .
- the delivery component 14 is configured to receive an additive and deliver the additive to the reservoir 16 .
- the delivery component 14 is connected to the flow generator 12 by the tube 20 and receives air flow from the generator 12 through the tube.
- the additive is added to the delivery component 14 through the inlet port 26 .
- the additive is then mixed with the air flow and delivered to the reservoir 16 through the tube 22 .
- the additive is delivered through the tube 22 to the reservoir 16 separately from the air flow.
- the delivery component 14 is configured to deliver the additive over time to the reservoir 16 at a metered or regulated rate using the metering component 28 . That is, the metering component 28 is configured to regulate or control over time the amount of additive that is delivered to the reservoir 16 .
- the metering component 28 is a metering dial similar to the device used to control intravenous injection flow rates, as discussed above.
- the metering component 28 is a ball-valve system, as discussed above.
- any known system for timed metering or regulation of the flow of a fluid can be used with the present invention.
- the additive is delivered directly to the reservoir 16 without any metering or flow regulation.
- the reservoir 16 in accordance with one embodiment, is configured as disclosed above.
- the reservoir 16 can be any known reservoir used with CPAP machines to humidify air flow.
- the mask 18 is configured as described above.
- the mask 18 can be any known mask for use with CPAP machines to deliver the air flow to the patient.
- an aromatic additive as described above is added to the delivery component 14 .
- the air flow is generated by the generator 12 and provided to the delivery component 14 and then to the reservoir 16 .
- the aromatic additive is added to the delivery component 14 and then delivered to the reservoir 16 .
- the additive is delivered in a timed metering fashion or without flow regulation. The rate of delivery or the amount of the additive will vary depending on the additive and the size of the reservoir.
- the air is “humidified.” That is, a portion of the water and aromatic additive is taken up by the air and is delivered as a humidified air flow to the mask 18 .
- a therapeutic additive as described above is added to the delivery component 14 .
- the air flow is generated by the generator 12 and provided to the delivery component 14 and then to the reservoir 16 .
- the therapeutic additive is added to the delivery component 14 and then delivered to the reservoir 16 .
- the additive is delivered in a timed metering fashion or by any other method of flow regulation. Alternatively, the additive is delivered without flow regulation. The rate of delivery or the amount of the additive will vary depending on the prescribed application of the additive and the size of the reservoir.
- the air is “humidified.” That is, a portion of the water and therapeutic additive is taken up by the air and is delivered as a humidified air flow to the mask 18 .
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is a method and apparatus for delivering an additive with a continuous positive airway pressure (“CPAP”) machine. The invention includes mixing an additive with humidifier water and providing the additive to the patient with the CPAP machine. According to certain embodiments, the additive can be an aromatic additive or a therapeutic additive.
Description
- This application claims priority to U.S. Provisional Application No. 60/532,926, filed on Dec. 29, 2003, which is hereby incorporated herein by reference in its entirety.
- The present invention relates to treatments for Sleep Apnea. More specifically, the present invention relates to an improved CPAP machine and methods of using a CPAP machine to provide an aromatic or therapeutic additive in the air flow provided to the patient.
- Approximately twenty million people in the United States have been diagnosed with Sleep Apnea. Sleep Apnea is an over-relaxation of the soft tissue in the back of the throat that causes a cessation of breathing during sleep states. The breathing cessation can cause a lack of oxygen that results in drowsiness and sleep disorders during waking hours.
- One treatment for Sleep Apnea is a continuous positive airway pressure (“CPAP”) machine, which provides a continuous flow of air through the nostrils via a mask. The flow of air works to maintain an open airway. Sleep Apnea sufferers must wear the mask for the entire night. One common component of a CPAP machine is a humidifier. Prior to applying the flow of air to the patient, the air is passed through the humidifier to add moisture to the air, thus helping to prevent the patient's nasal passages from drying out.
- One disadvantage of existing CPAP machines is that the moist air that is provided to the patient is often stale or even has an unpleasant smell or taste. A further disadvantage is that the existing machines provide nothing more than moist air to the patient.
- There is a need in the art for a CPAP machine that provides a pleasant tasting or smelling flow of air to the patient. There is a further need for a CPAP machine that is capable of providing more than just moist air.
- The present invention, in one embodiment, is a method of delivering additive with a continuous positive airway pressure (“CPAP”) machine. The method includes mixing an additive with humidifier water and providing the additive to the patient with the CPAP machine. According to an alternative embodiment, the additive can be an aromatic additive or a therapeutic additive.
- The present invention, in another embodiment, is an apparatus for delivering an additive to a continuous positive airway pressure (“CPAP”) machine. The apparatus includes an additive delivery device associated with a reservoir of the CPAP machine. According to one embodiment, the apparatus also includes a flow control device associated with the delivery device and configured to control delivery of the additive to the CPAP machine.
- In a further embodiment, the present invention is a packaged formulation for delivering an additive in a continuous positive airway pressure (“CPAP”) machine. The formulation includes an additive and instructions for use of the additive with the CPAP machine. According to one embodiment, the additive is an aromatic additive or a therapeutic additive.
- While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the invention is capable of modifications in various obvious aspects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
-
FIG. 1 is a schematic diagram of a CPAP machine, according to one embodiment of the present invention. -
FIG. 2 is a schematic diagram of a CPAP machine, according to an alternative embodiment of the present invention. - The present invention relates to an improved CPAP machine and a method of providing air flow to a patient having an aromatic or therapeutic additive. The aromatic additive provides a pleasant aroma to the air flow delivered to the patient, thus eliminating any unpleasant smell or taste associated with the air delivered by the CPAP machine. Further, the therapeutic additive allows the patient to receive treatment not only for Sleep Apnea, but also for any other illness that can be treated by inhalation of an appropriate substance.
-
FIG. 1 depicts aCPAP machine 50 according to one embodiment of the present invention. Themachine 50 has aflow generator 52, areservoir 56, and amask 18. Thedelivery component 14 has aninlet port 26 and ametering component 62. Atube 54 connects theflow generator 52 to thereservoir 56, and atube 60 connects thereservoir 56 to themask 62. - According to one embodiment, the
flow generator 52 is configured to create an air flow that is provided to thereservoir 56 and then themask 62 via the 54, 60. Thetubes flow generator 52 can be any known flow generator for a CPAP machine. - In accordance with one aspect of the invention, the additive is added to the
reservoir 56 through theinlet port 58. According to one embodiment, ametering component 64 is configured to deliver the additive over time to thereservoir 56 at a metered or regulated rate. That is, themetering component 64 is configured to regulate or control over time the amount of additive that is delivered to thereservoir 56. In one aspect of the invention, themetering component 64 is a metering dial similar to the device used to control intravenous injection flow rates. That is, the additive is placed into a flow line that passes through the dial and is regulated by turning the dial to pinch or open the line, thereby regulating the amount of additive that can pass through. - Alternatively, the
metering component 64 is a ball-valve system, in which a canal that allows flow of the additive can be blocked by a ball in the canal. The ball is configured to have at least one hole in it, and the ball can be turned by use of a handle connected to the ball. When the ball is turned so that the hole creates a passage in the canal, flow of the additive through the canal occurs. When the ball is turned so that the canal is completely blocked, flow of the additive is blocked. Further, the amount of flow can be regulated by regulating the size of the passage by controlling how much the ball is turned in the canal. Further, this device can be turned to provide various sized holes, thus allowing the additive to flow through to thereservoir 56 at a controlled rate. In a further alternative, any known system for timed metering or regulation of the flow of a fluid can be used with the present invention. In yet another alternative, the additive is delivered directly to thereservoir 56 without any metering or flow regulation. - The
reservoir 56, in accordance with one embodiment, is configured to hold water and receive into the water the additive delivered through theinlet port 58. Thus, thereservoir 56 is configured to allow the mixing of the additive into the water. Air flow passes through thereservoir 56 from theflow generator 52 to themask 62. Thereservoir 56 is configured to allow the air flow to take up moisture in the form of the water and additive (be “humidified” with the water and additive) and further allow that air flow to pass out of thereservoir 56 and to themask 62. Thereservoir 56 can be any known reservoir used with CPAP machines to humidify air flow. - The
mask 62 is configured to be placed on the patient's face and deliver the humidified air flow with the additive to the patient in such a fashion as to prevent Sleep Apnea. Themask 62 can be any known mask for use with CPAP machines to deliver the air flow to the patient. - In use, according to one embodiment of the present invention, an aromatic additive is added to the
inlet port 58. The additive is in concentrate form. Alternatively, the additive is in pre-mixed form. In a further alternative, the additive is in any form capable of being added to the CPAP machine. - The aromatic additive, in accordance with one aspect of the invention, is a fragrance. The additive can be chosen from, but is not limited to, any of the following aromatic additives, including lilac, evergreen, menthol, jasmine, eucalyptus, floral, lemon, lime, orange, tangerine, peppermint, strawberry, cherry, anise, honey, mint, vanilla, mocha. Alternatively, the aromatic additive is any known pleasant fragrance that can make the air flow more pleasant for the patient.
- The air flow is generated by the
flow generator 52 and provided to thereservoir 56. The aromatic additive is added to thereservoir 56. The additive is delivered in a timed metering fashion or by any other method of flow regulation. Alternatively, the additive is delivered without flow regulation. The rate of delivery or the amount of the additive will vary depending on the additive and the size of the reservoir. As the air flow passes through thereservoir 56, the air is “humidified.” That is, a portion of the water and aromatic additive is taken up by the air and is delivered as a humidified air flow to themask 62. - According to an alternative embodiment of the present invention, a therapeutic additive is added to the
reservoir 56. The additive is in concentrate form. Alternatively, the additive is in pre-mixed form. In a further alternative, the additive is in any form capable of being added to the CPAP machine. - The therapeutic additive, in accordance with one aspect of the invention, is any substance with therapeutic effect that can be administered by inhalation. The additive can be chosen from, but is not limited to, any substance that treats any of the following ailments or illnesses, including sinus ailments, throat ailments, chest ailments, headaches, allergies, flu, cold, menstrual cramps, and insomnia. Further, the additive can be chosen from, but is not limited to, any of the following therapeutic substances, including antihistamines, decongestants, anti-inflammatories, anti-depressants, vitamins, glucose, and chloraseptics. Alternatively, the therapeutic additive is any known substance having therapeutic effects that can be administered to the patient by inhalation.
- Several exemplary therapeutic additives, which shall not be considered limiting, include such respiratory-related, flu-related, and cold-related medications as products sold under brand names such as Robitussin®, Vicks®, TheraFlu®, Sudafed®, Contact®, Comtrex®, ZICAM®, Alka Seltzer®, Advil®, and Aleve®. Non-limiting exemplary additives for allergy relief, including some prescription medications, include certain products sold under brand names such as Chlor-Trimetor®, Advil®, Benadryl®, Claritin-D®, Claritin®, Allegra®, Nasacort®, Nasanex®, and Zyrtec®. Non-limiting exemplary additives for pain relief, including some prescription medications, include certain products sold under brand names such as Tylenol®, Motrin®, Advil®, Excedrin®, Aleve®, Celebrex®, Vioxx®, Flextra-DS®, Fioricet®, and Tramadol®. Non-limiting exemplary additives for menstrual relief include certain products sold under the brand name Pamprin®. Non-limiting exemplary additives for women's health, including some prescription medications, include certain products sold under such brand names as Ortho Tri-Cyclen®,
Nordette 28®, Triphasil®, Diflucan®, and Estradiol®. Non-limiting exemplary sleep aid additives, including some prescription medications, include certain products sold under such brand names as Unisom®, Ambier®, and Sonata®. Non-limiting exemplary additives for arthritic relief include certain products sold under the brand name Tylenol®. Non-limiting exemplary vitamin additives include all known vitamins such as A, B-12, C, E, etc. Non-limiting exemplary vitamin additives include certain products sold under such brand names as Centrum®, Rexall®, Sundown®, Nature Made®, Natures Valley®, and Swanson Health®. Non-limiting exemplary additives for relief from viruses and/or infections, including some prescription medications, include such products as penicillin and amoxicillin. Non-limiting exemplary muscle-relaxant additives, including some prescription medications, include products sold under such brand names as Skelaxin®, Soma®, Flexeril®, and Zanflex®. Non-limiting exemplary additives for anxiety or depression, including some prescription medications, include products under such brand names as Buspar®, Paxil®, Prozac®, Zoloft®, Wellbutrin®, and Celexa®. Non-limiting exemplary skin care additives, including some prescription medications, include products such as retin A and products under such brand names as Renova®. Non-limiting exemplary additives for sexual or genital health, including some prescription medications, include products under such brand names as Acyclovir® and Valtrex®. Non-limiting exemplary smoke-cessation additives, including some prescription medications, include products under the brand name Zyban®. - The air flow is generated by the
flow generator 52 and provided to thereservoir 56. The therapeutic additive is added to thereservoir 56. The additive is delivered in a timed metering fashion or by any other method of flow regulation. Alternatively, the additive is delivered without flow regulation. The rate of delivery or the amount of the additive will vary depending on the prescribed application of the additive and the size of the reservoir. As the air flow passes through thereservoir 56, the air is “humidified.” That is, a portion of the water and therapeutic additive is taken up by the air and is delivered as a humidified air flow to themask 62. - In accordance with one alternative aspect of the invention, any aromatic or therapeutic additive disclosed herein can be added to the reservoir of any existing CPAP machine. The additive is provided in pre-mixed form. Alternatively, the additive is provided in concentrate form. In a further alternative, the additive is in any form capable of being added to the reservoir of any existing CPAP machine.
-
FIG. 2 depicts aCPAP machine 10 according to an alternative embodiment of the present invention. Themachine 10 has aflow generator 12, adelivery component 14, areservoir 16, and amask 18. Thedelivery component 14 has aninlet port 26 and ametering component 28. Atube 20 connects theflow generator 12 to thedelivery component 14, while atube 22 connects thedelivery component 14 to thereservoir 16, and atube 24 connects thereservoir 16 to themask 18. - According to one embodiment, the
flow generator 12 is configured to create an air flow that is provided through thedelivery component 14 to thereservoir 16 and then themask 18 via the 20, 22, 24.tubes - The
delivery component 14, according to one embodiment, is configured to receive an additive and deliver the additive to thereservoir 16. Thedelivery component 14 is connected to theflow generator 12 by thetube 20 and receives air flow from thegenerator 12 through the tube. In accordance with one aspect of the invention, the additive is added to thedelivery component 14 through theinlet port 26. The additive is then mixed with the air flow and delivered to thereservoir 16 through thetube 22. Alternatively, the additive is delivered through thetube 22 to thereservoir 16 separately from the air flow. - The
delivery component 14, according to one embodiment, is configured to deliver the additive over time to thereservoir 16 at a metered or regulated rate using themetering component 28. That is, themetering component 28 is configured to regulate or control over time the amount of additive that is delivered to thereservoir 16. In one aspect of the invention, themetering component 28 is a metering dial similar to the device used to control intravenous injection flow rates, as discussed above. Alternatively, themetering component 28 is a ball-valve system, as discussed above. In a further alternative, any known system for timed metering or regulation of the flow of a fluid can be used with the present invention. In yet another alternative, the additive is delivered directly to thereservoir 16 without any metering or flow regulation. - The
reservoir 16, in accordance with one embodiment, is configured as disclosed above. Thereservoir 16 can be any known reservoir used with CPAP machines to humidify air flow. - The
mask 18, according to one aspect of the invention, is configured as described above. Themask 18 can be any known mask for use with CPAP machines to deliver the air flow to the patient. - In use, according to one embodiment of the present invention, an aromatic additive as described above is added to the
delivery component 14. The air flow is generated by thegenerator 12 and provided to thedelivery component 14 and then to thereservoir 16. The aromatic additive is added to thedelivery component 14 and then delivered to thereservoir 16. The additive is delivered in a timed metering fashion or without flow regulation. The rate of delivery or the amount of the additive will vary depending on the additive and the size of the reservoir. As the air flow passes through thereservoir 16, the air is “humidified.” That is, a portion of the water and aromatic additive is taken up by the air and is delivered as a humidified air flow to themask 18. - According to an alternative embodiment of the present invention, a therapeutic additive as described above is added to the
delivery component 14. The air flow is generated by thegenerator 12 and provided to thedelivery component 14 and then to thereservoir 16. The therapeutic additive is added to thedelivery component 14 and then delivered to thereservoir 16. The additive is delivered in a timed metering fashion or by any other method of flow regulation. Alternatively, the additive is delivered without flow regulation. The rate of delivery or the amount of the additive will vary depending on the prescribed application of the additive and the size of the reservoir. As the air flow passes through thereservoir 16, the air is “humidified.” That is, a portion of the water and therapeutic additive is taken up by the air and is delivered as a humidified air flow to themask 18. - Although the present invention has been described with reference to preferred embodiments, persons skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
Claims (16)
1-16. (canceled)
17. A method of delivering additive with a continuous positive airway pressure (“CPAP”) machine comprising:
mixing an additive with humidifier water using an additive delivery device; and
providing the additive to the patient with the CPAP machine, wherein a portion of the water and additive are taken up by the air in the CPAP machine and delivered as a humidified air flow to a CPAP machine mask.
18. The method of claim 17 wherein the additive is an aromatic additive.
19. The method of claim 17 wherein the additive is a therapeutic additive.
20. An additive delivery apparatus for delivering an additive to a fluid reservoir of a continuous positive airway pressure (“CPAP”) machine comprising:
an additive delivery device configured to be arranged on the fluid reservoir, the additive delivery device comprising:
an additive inlet port configured to be coupled to the fluid reservoir in an area between an air flow inlet and air flow outlet of the CPAP machine, the additive inlet port for introducing the additive to the fluid reservoir; and
a flow control device configured to be in fluid communication with the additive inlet port, the flow control device for controlling delivery of the additive to the CPAP machine.
21. The apparatus of claim 20 wherein the flow control device is a metering dial.
22. The apparatus of claim 20 wherein the flow control device is a ball-valve system.
23. The apparatus of claim 20 wherein the additive is an aromatic additive.
24. The apparatus of claim 20 wherein the additive is a therapeutic additive.
25. An apparatus for delivering an additive to a continuous positive airway pressure (“CPAP”) machine comprising:
a reservoir configured with an air flow inlet and an air flow outlet;
an additive delivery component associated with the reservoir, the delivery component comprising:
an additive inlet port arranged at the air flow inlet; and
a metering component in fluid communication with the inlet port the metering component configured to meter the additive to the fluid in the fluid reservoir.
26. The apparatus of claim 25 wherein the additive is an aromatic additive.
27. The apparatus of claim 25 wherein the additive is a therapeutic additive.
28. The apparatus of claim 25 wherein the metering component is a metering dial.
29. The apparatus of claim 25 wherein the metering component is a ball-valve system.
30. The apparatus of claim 25 wherein the delivery component is integral with the reservoir.
31. The apparatus of claim 25 wherein the delivery component is operably coupled with the reservoir by a tube.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/035,818 US20080196711A1 (en) | 2003-12-29 | 2008-02-22 | Method and apparatus for delivering an additive with a cpap machine |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53292603P | 2003-12-29 | 2003-12-29 | |
| US11/001,777 US7350519B2 (en) | 2003-12-29 | 2004-12-02 | Method and apparatus for delivering an additive with a CPAP machine |
| US12/035,818 US20080196711A1 (en) | 2003-12-29 | 2008-02-22 | Method and apparatus for delivering an additive with a cpap machine |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/001,777 Continuation US7350519B2 (en) | 2003-12-29 | 2004-12-02 | Method and apparatus for delivering an additive with a CPAP machine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20080196711A1 true US20080196711A1 (en) | 2008-08-21 |
Family
ID=34703529
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/001,777 Expired - Fee Related US7350519B2 (en) | 2003-12-29 | 2004-12-02 | Method and apparatus for delivering an additive with a CPAP machine |
| US12/035,818 Abandoned US20080196711A1 (en) | 2003-12-29 | 2008-02-22 | Method and apparatus for delivering an additive with a cpap machine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/001,777 Expired - Fee Related US7350519B2 (en) | 2003-12-29 | 2004-12-02 | Method and apparatus for delivering an additive with a CPAP machine |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US7350519B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011082346A3 (en) * | 2009-12-31 | 2011-11-03 | Doelling Eric N | Devices, systems, and methods for monitoring, analyzing, and/or adjusting sleep conditions |
| US20180008796A1 (en) * | 2015-02-08 | 2018-01-11 | Son Q. Le | Scent delivery adaptor for cpap |
| WO2021183903A1 (en) * | 2020-03-13 | 2021-09-16 | Separation Design Group Llc | Portable ventilator |
| US20220401673A1 (en) * | 2019-10-31 | 2022-12-22 | Resmed Sensor Technologies Limited | Systems and methods for injecting substances into a respiratory system |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7350519B2 (en) * | 2003-12-29 | 2008-04-01 | Timothy Alan Duncan | Method and apparatus for delivering an additive with a CPAP machine |
| US20060118114A1 (en) * | 2004-12-06 | 2006-06-08 | Hinkle Allen J | Scented anesthesia breathing circuit |
| NZ541134A (en) * | 2005-07-04 | 2007-10-26 | Lifevent Medical Ltd | Continuous positive airway pressure device with constant pressure applied on breathable air reservoir |
| US20110056493A1 (en) * | 2009-09-10 | 2011-03-10 | Kim Iola Miller | Sleep apnea vapor inhaler adapter |
| US9314582B2 (en) * | 2010-11-23 | 2016-04-19 | Carefusion 2200, Inc. | Humidification system |
| WO2018053079A1 (en) * | 2016-09-14 | 2018-03-22 | Bogan Consulting Services, P.A. | Therapeutic device for treatment of conditions relating to the sinuses, nasal cavities, ear, nose and throat |
| US11432993B2 (en) | 2016-09-14 | 2022-09-06 | Healthy Humming, LLC | Therapeutic device for treatment of conditions relating to the sinuses, nasal cavities, ear, nose and throat |
| US11213641B2 (en) | 2016-09-14 | 2022-01-04 | Healthy Humming, LLC | Therapeutic device for treatment of conditions relating to the sinuses, nasal cavities, ear, nose and throat |
| US11305077B2 (en) | 2016-09-14 | 2022-04-19 | Healthy Humming, LLC | Therapeutic device for treatment of conditions relating to the sinuses, nasal cavities, ear, nose and throat |
| WO2020185977A1 (en) * | 2019-03-11 | 2020-09-17 | Health Research, Inc. | Medicinal nebulizer and method of dispensing medicament |
Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3590857A (en) * | 1970-01-21 | 1971-07-06 | Oil Rite Corp | Constant level liquid supply means |
| US4200093A (en) * | 1978-04-20 | 1980-04-29 | Nat Camp | Steam-air inhalator |
| US4752422A (en) * | 1986-06-06 | 1988-06-21 | Uchida Manufacturing Co., Ltd. | Ultrasonic humidifier |
| US5065753A (en) * | 1990-05-04 | 1991-11-19 | Calvin Kalishman | Air-moisture generation system |
| US5231979A (en) * | 1992-02-14 | 1993-08-03 | Puritan-Bennett Corporation | Humidifier for CPAP device |
| US5673687A (en) * | 1995-06-07 | 1997-10-07 | Respironics, Inc. | Humidifier for a ventilator and an associated attachment |
| US6000394A (en) * | 1994-10-26 | 1999-12-14 | Paul Rizau Pari-Werk Gmbh | Generation of an aerosol of an exact dose |
| US20020020930A1 (en) * | 2000-08-14 | 2002-02-21 | Gary Austin | CPAP humidifier |
| US20030053956A1 (en) * | 2001-01-24 | 2003-03-20 | Thomas Hofmann | Alkylaryl polyether alcohol polymers for treatment and prophylaxis of snoring, sleep apnea, sudden infant death syndrome and for improvement of nasal breathing |
| US20030066526A1 (en) * | 2000-03-21 | 2003-04-10 | Mohammad Thudor | Apparatus for delivering humidified gases |
| US20040016432A1 (en) * | 2001-02-06 | 2004-01-29 | Harald Genger | Anti-snoring device, method for reducing snoring, and a nasal air cannula |
| US6718974B1 (en) * | 2000-10-06 | 2004-04-13 | Mallinckrodt, Inc. | CPAP humidifier having sliding access door |
| US20040107964A1 (en) * | 2001-04-12 | 2004-06-10 | Shaw Geoffrey Mark | Continuous positive airway pressure device |
| US20040210153A1 (en) * | 2003-04-15 | 2004-10-21 | Ross Tsukashima | Respiratory monitoring, diagnostic and therapeutic system |
| US20040226562A1 (en) * | 2002-12-06 | 2004-11-18 | Bordewick Steven S. | Blower assembly for CPAP |
| US6976489B2 (en) * | 2000-06-30 | 2005-12-20 | Northgate Technologies, Inc. | Method and apparatus for humidification and warming of air |
| US20060113690A1 (en) * | 2002-08-30 | 2006-06-01 | Huddart Brett J | Humidification system |
| US7096864B1 (en) * | 1999-08-05 | 2006-08-29 | Map Medizin-Technologie Gmbh | Device for supplying respiratory gas |
| US7137388B2 (en) * | 2001-02-16 | 2006-11-21 | Resmed Limited | Air pressure signal monitoring in apparatus for treating sleep disordered breathing |
| US20070119454A1 (en) * | 1991-12-20 | 2007-05-31 | Resmed Limited | Patient interface assembly for CPAP respiratory apparatus |
| US20070125376A1 (en) * | 2004-08-04 | 2007-06-07 | Jurgen Reinstadtler | Evaporator, artificial respiration apparatus and evaporation process |
| US7350519B2 (en) * | 2003-12-29 | 2008-04-01 | Timothy Alan Duncan | Method and apparatus for delivering an additive with a CPAP machine |
-
2004
- 2004-12-02 US US11/001,777 patent/US7350519B2/en not_active Expired - Fee Related
-
2008
- 2008-02-22 US US12/035,818 patent/US20080196711A1/en not_active Abandoned
Patent Citations (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3590857A (en) * | 1970-01-21 | 1971-07-06 | Oil Rite Corp | Constant level liquid supply means |
| US4200093A (en) * | 1978-04-20 | 1980-04-29 | Nat Camp | Steam-air inhalator |
| US4752422A (en) * | 1986-06-06 | 1988-06-21 | Uchida Manufacturing Co., Ltd. | Ultrasonic humidifier |
| US5065753A (en) * | 1990-05-04 | 1991-11-19 | Calvin Kalishman | Air-moisture generation system |
| US20070119454A1 (en) * | 1991-12-20 | 2007-05-31 | Resmed Limited | Patient interface assembly for CPAP respiratory apparatus |
| US5231979A (en) * | 1992-02-14 | 1993-08-03 | Puritan-Bennett Corporation | Humidifier for CPAP device |
| US6000394A (en) * | 1994-10-26 | 1999-12-14 | Paul Rizau Pari-Werk Gmbh | Generation of an aerosol of an exact dose |
| US5673687A (en) * | 1995-06-07 | 1997-10-07 | Respironics, Inc. | Humidifier for a ventilator and an associated attachment |
| US7096864B1 (en) * | 1999-08-05 | 2006-08-29 | Map Medizin-Technologie Gmbh | Device for supplying respiratory gas |
| US20030066526A1 (en) * | 2000-03-21 | 2003-04-10 | Mohammad Thudor | Apparatus for delivering humidified gases |
| US6976489B2 (en) * | 2000-06-30 | 2005-12-20 | Northgate Technologies, Inc. | Method and apparatus for humidification and warming of air |
| US20020020930A1 (en) * | 2000-08-14 | 2002-02-21 | Gary Austin | CPAP humidifier |
| US6718974B1 (en) * | 2000-10-06 | 2004-04-13 | Mallinckrodt, Inc. | CPAP humidifier having sliding access door |
| US20030053956A1 (en) * | 2001-01-24 | 2003-03-20 | Thomas Hofmann | Alkylaryl polyether alcohol polymers for treatment and prophylaxis of snoring, sleep apnea, sudden infant death syndrome and for improvement of nasal breathing |
| US20040016432A1 (en) * | 2001-02-06 | 2004-01-29 | Harald Genger | Anti-snoring device, method for reducing snoring, and a nasal air cannula |
| US7137388B2 (en) * | 2001-02-16 | 2006-11-21 | Resmed Limited | Air pressure signal monitoring in apparatus for treating sleep disordered breathing |
| US20040107964A1 (en) * | 2001-04-12 | 2004-06-10 | Shaw Geoffrey Mark | Continuous positive airway pressure device |
| US20060113690A1 (en) * | 2002-08-30 | 2006-06-01 | Huddart Brett J | Humidification system |
| US20040226562A1 (en) * | 2002-12-06 | 2004-11-18 | Bordewick Steven S. | Blower assembly for CPAP |
| US20040210153A1 (en) * | 2003-04-15 | 2004-10-21 | Ross Tsukashima | Respiratory monitoring, diagnostic and therapeutic system |
| US7350519B2 (en) * | 2003-12-29 | 2008-04-01 | Timothy Alan Duncan | Method and apparatus for delivering an additive with a CPAP machine |
| US20070125376A1 (en) * | 2004-08-04 | 2007-06-07 | Jurgen Reinstadtler | Evaporator, artificial respiration apparatus and evaporation process |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011082346A3 (en) * | 2009-12-31 | 2011-11-03 | Doelling Eric N | Devices, systems, and methods for monitoring, analyzing, and/or adjusting sleep conditions |
| US20180008796A1 (en) * | 2015-02-08 | 2018-01-11 | Son Q. Le | Scent delivery adaptor for cpap |
| US10682487B2 (en) * | 2015-02-08 | 2020-06-16 | Cpap Infusion, Llc | Scent delivery adaptor for CPAP |
| US20220401673A1 (en) * | 2019-10-31 | 2022-12-22 | Resmed Sensor Technologies Limited | Systems and methods for injecting substances into a respiratory system |
| WO2021183903A1 (en) * | 2020-03-13 | 2021-09-16 | Separation Design Group Llc | Portable ventilator |
| US20230173214A1 (en) * | 2020-03-13 | 2023-06-08 | Separation Design Group Llc | Portable ventilator |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050139221A1 (en) | 2005-06-30 |
| US7350519B2 (en) | 2008-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080196711A1 (en) | Method and apparatus for delivering an additive with a cpap machine | |
| US10646668B2 (en) | Pulsating inhaler and a method of treating upper respiratory disorders | |
| US7984714B2 (en) | Managing obstructive sleep apnea and/or snoring using local time released agents | |
| US20180344951A1 (en) | Device and method for aerosolized delivery of substance to a natural orifice of the body | |
| DE60330601D1 (en) | POWDER INHALER WITH SUMATRIPTAN AND MANUFACTURING METHOD THEREFOR | |
| US20080156319A1 (en) | Pulsating Inhaler and a Method of Treating Upper Respiratory Disorders | |
| JP2010537696A (en) | Nostril insertion device | |
| KR20010020346A (en) | Method of delivering halotherapy | |
| CA2519175A1 (en) | A method of treating a systemic disease | |
| JP4173538B2 (en) | Nasal and ophthalmic administration of ketamine for pain management and detoxification | |
| US7299802B2 (en) | Carbon dioxide delivery apparatus and method for using same | |
| US9272036B2 (en) | Carbon dioxide, saline and additional active nasal delivery methods and treatments | |
| CN105055518A (en) | Traditional Chinese medicine fumigant for treating child rhinitis | |
| US20170360831A1 (en) | Non-nasal treatment methods using carbon dioxide and saline | |
| JPS5995055A (en) | Nitrous oxide sucking tranquilizer | |
| CN101124007B (en) | Devices and methods for facilitating direct delivery of gaseous particles into nasal passages | |
| Janiani et al. | Assessment of pain during pediatric dental treatment using different sedative agents: a crossover trial | |
| US20170224936A1 (en) | Nasal treatment delivery device with carbon dioxide and saline, and methods | |
| US20060210482A1 (en) | Chemical composition and method for cold and sinus relief | |
| DE202015003981U1 (en) | Compact nebulizer for inhalation of active ingredients for veterinary use | |
| CN110201082A (en) | A kind of Chinese medicine composition and its external preparation that rhinitis is stifling | |
| CA3013821C (en) | Nasal treatment delivery device with carbon dioxide and saline, and methods, including low flow rates | |
| KR20050011371A (en) | Functional PAS | |
| CA3167084A1 (en) | Method, apparatus and kit for treating chronic and long-term nasal congestion | |
| US10029054B2 (en) | Lower body cavity treatment methods and devices using carbon dioxide and saline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |